Sugi Predict

Sugi Predict / Compounds / SCHEMBL1812286

SCHEMBL1812286

SCHEMBL1812286

COCCN1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.62
▸ GFER P55789 4/20 0.62
▸ KDM4E B2RXH2 3/20 0.62
▸ GAA P10253 3/20 0.62
▸ SMN1; SMN2 Q16637 2/20 0.62
▸ RAD52 P43351 1/20 0.62
▸ ALDH1A1 P00352 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ ADRA2C P18825 1/20 0.58
▸ PTK2B Q14289 1/20 0.58
▸ ESR2 Q92731 1/20 0.58
▸ DRD2 P14416 3/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ HTT P42858 2/20 0.49
▸ LMNA P02545 2/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ MAP4K4 O95819 1/20 0.47
▸ CASP6 P55212 1/20 0.46
▸ L3MBTL1 Q9Y468 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6151540 1.00 MAPT (0.62) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL14431527 0.94 MAPT (0.55) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL23126630 0.86 MAPT (0.46) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL8350747 0.85 MAPT (0.58) MAPTGFERALDH1A1DRD2HSD17B10
SCHEMBL12089874 0.84 KDM2B (0.55) MAPTKDM4EGAAALDH1A1KMT2A
SCHEMBL1809859 0.84 KDM4E (0.63) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL19099996 0.83 DRD2 (0.73) MAPTKDM4EALDH1A1KMT2ADRD2
SCHEMBL29964154 0.83 DRD2 (0.51) MAPTGFERKDM4EGAASMN1; SMN2
SCHEMBL24681554 0.83 KDM4E (0.60) MAPTKDM4EGAAKMT2ADRD2
SCHEMBL2651949 0.83 ADRA2C (0.61) MAPTSMN1; SMN2ALDH1A1ADRA2CDRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003047575-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 — — WO claimed
WO-2003048121-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 — — WO claimed
WO-2024105364-A1 HETEROCYCLIC INHIBITORS OF CDC-LIKE KINASES CURADEV PHARMA LTD (GB) 2024-05-23 — — WO disclosed
EP-4327886-A2 PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF Libertas Bio, Inc. (US) 2024-02-28 — — EP disclosed
CN-117486865-A Pyrimidine derivatives as kinase inhibitors 艾森医药公司 2024-02-02 — — CN disclosed
CN-112592334-B Pyrimidine derivatives as kinase inhibitors 艾森医药公司 2023-10-27 — — CN disclosed
EP-3392252-B1 PYRIMIDO- PYRIDAZINONE COMPOUNDS AND USE THEREOF LIBERTAS BIO INC (US) 2023-10-04 — — EP disclosed
EP-3564232-B1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2022-01-26 — — EP disclosed
US-10954216-B2 BMP-signal-inhibiting compound RIKEN (JP) 2021-03-23 — — US disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 — — US disclosed
US-10562918-B2 Heterocyclic compounds and uses thereof ACEA Therapeutics, Inc. (US) 2020-02-18 — — US disclosed
US-7094896-B2 Diaminothiazoles having antiproliferative activity HOFFMANN-LA ROCHE INC. (US) 2006-08-22 — — US disclosed
EP-1358169-B1 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE HOFFMANN LA ROCHE (CH) 2006-01-11 — — EP disclosed
US-6756374-B2 CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS HOFFMANN-LA ROCHE INC. 2004-06-29 — — US disclosed
US-20040087594-A1 Diaminothiazoles having antiproliferative activity DING QINGJIE (US) 2004-05-06 — — US disclosed
US-20040082595-A1 Intermediates useful in the preparation of diaminothiazoles DING QINGJIE (US) 2004-04-29 — — US disclosed
EP-1358169-A2 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE F. HOFFMANN-LA ROCHE AG (CH) 2003-11-05 — — EP disclosed
WO-2003047575-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 — — WO disclosed
US-20020151554-A1 Diaminothiazoles having antiproliferative activity CHEN LI (US) 2002-10-17 — — US disclosed
WO-2002057261-A2 DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE F. HOFFMANN-LA ROCHE AG (CH) 2002-07-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087594-A1 Diaminothiazoles having antiproliferative activity CDK4, CDK2, CDKL4 MAPT 3064/4885GFER 4289/4885KDM4E 973/4885
US-10954216-B2 BMP-signal-inhibiting compound BMP1, BMP2, BMP4 MAPT 4782/4885GFER 4662/4885KDM4E 1558/4885
US-10562918-B2 Heterocyclic compounds and uses thereof BMX, BLK, BTK MAPT 2803/4885GFER 2806/4885KDM4E 2158/4885
US-20020151554-A1 Diaminothiazoles having antiproliferative activity CDK4, CDK2, CDKL4 MAPT 3064/4885GFER 4289/4885KDM4E 973/4885
US-20040082595-A1 Intermediates useful in the preparation of diaminothiazoles CDK4, CDK2, CDKL4 MAPT 2939/4885GFER 3986/4885KDM4E 1021/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK MAPT 438/4885GFER 3792/4885KDM4E 1645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.